Friday, 16 October 2026European Markets

ELOPAK And 2 Other Stocks Have Very High Payout Ratio

Loading stream...

(vianews) - m.r.m (mrm.pa), elopak (elo.ol), manitou bf (mtu.pa) are the highest payout ratio stocks on this list.

here's the data we've collected of stocks with a high payout ratio so far. the payout ratio in itself isn't a promise of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to issue them.

when researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. m.r.m (mrm.pa)

73.34% payout ratio

earnings per share

as for profitability, m.r.m has a trailing twelve months eps of €-3.13.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -9.43%.

moving average

m.r.m's worth is way under its 50-day moving average of €20.06 and under its 200-day moving average of €18.23.

revenue growth

year-on-year quarterly revenue growth declined by 0.4%, now sitting on 15.13m for the twelve trailing months.

yearly top and bottom value

m.r.m's stock is valued at €17.20 at 16:10 est, way under its 52-week high of €35.20 and way higher than its 52-week low of €14.50.

more news about m.r.m.

2. elopak (elo.ol)

32.57% payout ratio

earnings per share

as for profitability, elopak has a trailing twelve months eps of kr3.09.

pe ratio

elopak has a trailing twelve months price to earnings ratio of 14.85. meaning, the purchaser of the share is investing kr14.85 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.46%.

moving average

elopak's worth is way above its 50-day moving average of kr22.63 and way higher than its 200-day moving average of kr23.47.

more news about elopak.

3. manitou bf (mtu.pa)

31.69% payout ratio

earnings per share

as for profitability, manitou bf has a trailing twelve months eps of €3.75.

pe ratio

manitou bf has a trailing twelve months price to earnings ratio of 6.76. meaning, the purchaser of the share is investing €6.76 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.56%.

volume

today's last reported volume for manitou bf is 6779 which is 52.26% below its average volume of 14202.

revenue growth

year-on-year quarterly revenue growth grew by 0.4%, now sitting on 2.88b for the twelve trailing months.

yearly top and bottom value

manitou bf's stock is valued at €25.35 at 16:10 est, way below its 52-week high of €29.00 and way higher than its 52-week low of €16.32.

more news about manitou bf.

1. 1 (1)

1% payout ratio

1

earnings per share

as for profitability, 1 has a trailing twelve months eps of €1.

pe ratio

1 has a trailing twelve months price to earnings ratio of 1. meaning, the purchaser of the share is investing €1 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

volatility

1's last week, last month's, and last quarter's current intraday variation average was 1.00%, 1.00%, and 1.00%.

1's highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).

more news about 1.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com